Samjin Pharmaceuticals Co., Ltd. (005500.KS)
KRW 18280.0
(-0.33%)
KRW 18280.0
(-0.33%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 419.9 Billion KRW | 3.28% |
| 2022 | 406.55 Billion KRW | 22.27% |
| 2021 | 332.49 Billion KRW | 23.59% |
| 2020 | 269.03 Billion KRW | 10.19% |
| 2019 | 244.15 Billion KRW | -2.45% |
| 2018 | 250.27 Billion KRW | 3.48% |
| 2017 | 241.84 Billion KRW | 6.27% |
| 2016 | 227.57 Billion KRW | 3.1% |
| 2015 | 220.73 Billion KRW | 5.46% |
| 2014 | 209.3 Billion KRW | 2.63% |
| 2013 | 203.94 Billion KRW | -0.12% |
| 2012 | 204.18 Billion KRW | -1.88% |
| 2011 | 208.1 Billion KRW | 8.83% |
| 2010 | 191.22 Billion KRW | 1.92% |
| 2009 | 187.61 Billion KRW | 5.06% |
| 2008 | 178.57 Billion KRW | 13.22% |
| 2007 | 157.72 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 420.25 Billion KRW | 0.08% |
| 2024 Q2 | 438.14 Billion KRW | 4.26% |
| 2023 Q4 | 419.9 Billion KRW | -0.67% |
| 2023 Q1 | 421.46 Billion KRW | 3.67% |
| 2023 Q2 | 421.77 Billion KRW | 0.07% |
| 2023 FY | 419.9 Billion KRW | 3.28% |
| 2023 Q3 | 422.72 Billion KRW | 0.23% |
| 2022 Q4 | 406.55 Billion KRW | 3.56% |
| 2022 Q2 | 354.71 Billion KRW | -0.17% |
| 2022 Q1 | 355.33 Billion KRW | 6.87% |
| 2022 FY | 406.55 Billion KRW | 22.27% |
| 2022 Q3 | 392.59 Billion KRW | 10.68% |
| 2021 Q3 | 325.34 Billion KRW | 11.28% |
| 2021 Q2 | 292.36 Billion KRW | 2.75% |
| 2021 FY | 332.49 Billion KRW | 23.59% |
| 2021 Q1 | 284.54 Billion KRW | 5.76% |
| 2021 Q4 | 332.49 Billion KRW | 2.2% |
| 2020 FY | 269.03 Billion KRW | 10.19% |
| 2020 Q3 | 269.57 Billion KRW | 2.94% |
| 2020 Q4 | 269.03 Billion KRW | -0.2% |
| 2020 Q1 | 256.85 Billion KRW | 5.2% |
| 2020 Q2 | 261.88 Billion KRW | 1.96% |
| 2019 Q4 | 244.15 Billion KRW | 1.95% |
| 2019 Q3 | 239.47 Billion KRW | -0.0% |
| 2019 FY | 244.15 Billion KRW | -2.45% |
| 2019 Q1 | 262.9 Billion KRW | 5.05% |
| 2019 Q2 | 239.48 Billion KRW | -8.91% |
| 2018 Q1 | 253.29 Billion KRW | 4.73% |
| 2018 Q3 | 264.83 Billion KRW | 5.46% |
| 2018 Q2 | 251.11 Billion KRW | -0.86% |
| 2018 Q4 | 250.27 Billion KRW | -5.5% |
| 2018 FY | 250.27 Billion KRW | 3.48% |
| 2017 Q3 | 237.18 Billion KRW | 4.01% |
| 2017 Q2 | 228.04 Billion KRW | -2.42% |
| 2017 Q1 | 233.7 Billion KRW | 2.69% |
| 2017 FY | 241.84 Billion KRW | 6.27% |
| 2017 Q4 | 241.84 Billion KRW | 1.96% |
| 2016 Q1 | 219.93 Billion KRW | -0.36% |
| 2016 Q3 | 220.45 Billion KRW | 2.14% |
| 2016 Q2 | 215.82 Billion KRW | -1.87% |
| 2016 Q4 | 227.57 Billion KRW | 3.23% |
| 2016 FY | 227.57 Billion KRW | 3.1% |
| 2015 FY | 220.73 Billion KRW | 5.46% |
| 2015 Q4 | 220.73 Billion KRW | -0.82% |
| 2015 Q3 | 222.56 Billion KRW | 2.76% |
| 2015 Q2 | 216.58 Billion KRW | 0.24% |
| 2015 Q1 | 216.06 Billion KRW | 3.23% |
| 2014 Q2 | 207.58 Billion KRW | 0.76% |
| 2014 Q3 | 209.35 Billion KRW | 0.85% |
| 2014 FY | 209.3 Billion KRW | 2.63% |
| 2014 Q4 | 209.3 Billion KRW | -0.02% |
| 2014 Q1 | 206.02 Billion KRW | 1.02% |
| 2013 Q3 | 210.81 Billion KRW | 0.28% |
| 2013 Q4 | 203.94 Billion KRW | -3.26% |
| 2013 FY | 203.94 Billion KRW | -0.12% |
| 2013 Q1 | 207.9 Billion KRW | 1.82% |
| 2013 Q2 | 210.23 Billion KRW | 1.12% |
| 2012 Q2 | 196.65 Billion KRW | -3.56% |
| 2012 Q1 | 203.9 Billion KRW | -2.02% |
| 2012 FY | 204.18 Billion KRW | -1.88% |
| 2012 Q4 | 204.18 Billion KRW | 3.13% |
| 2012 Q3 | 197.98 Billion KRW | 0.68% |
| 2011 Q3 | 215.54 Billion KRW | 2.38% |
| 2011 Q4 | 208.1 Billion KRW | -3.45% |
| 2011 FY | 208.1 Billion KRW | 8.83% |
| 2011 Q1 | 207.03 Billion KRW | 8.27% |
| 2011 Q2 | 210.54 Billion KRW | 1.69% |
| 2010 Q4 | 191.22 Billion KRW | -2.59% |
| 2010 Q3 | 196.29 Billion KRW | 0.62% |
| 2010 FY | 191.22 Billion KRW | 1.92% |
| 2010 Q1 | 195.28 Billion KRW | 4.08% |
| 2010 Q2 | 195.08 Billion KRW | -0.1% |
| 2009 Q2 | 188.67 Billion KRW | 1.42% |
| 2009 FY | 187.61 Billion KRW | 5.06% |
| 2009 Q4 | 187.61 Billion KRW | -2.07% |
| 2009 Q3 | 191.59 Billion KRW | 1.55% |
| 2009 Q1 | 186.02 Billion KRW | 4.17% |
| 2008 Q4 | 178.57 Billion KRW | 0.17% |
| 2008 Q2 | 170.12 Billion KRW | -0.88% |
| 2008 Q1 | 171.62 Billion KRW | 8.82% |
| 2008 Q3 | 178.26 Billion KRW | 4.79% |
| 2008 FY | 178.57 Billion KRW | 13.22% |
| 2007 Q1 | 153.94 Billion KRW | 0.0% |
| 2007 FY | 157.72 Billion KRW | 0.0% |
| 2007 Q4 | 157.72 Billion KRW | -3.88% |
| 2007 Q3 | 164.08 Billion KRW | 4.98% |
| 2007 Q2 | 156.3 Billion KRW | 1.54% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -111.843% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 78.545% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 52.121% |
| HANDOK Inc. | 790.33 Billion KRW | 46.871% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -146.103% |
| Yuhan Corporation | 2814.07 Billion KRW | 85.079% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 68.074% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -349.193% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 78.489% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -75.143% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 10.45% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -265.216% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -77.511% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -20.528% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -111.843% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -0.17% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 15.982% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 28.757% |
| JW Holdings Corporation | 1176.26 Billion KRW | 64.302% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 31.306% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 70.059% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 34.903% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -19.943% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -172.59% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -13.279% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 13.836% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -111.843% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 61.05% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 76.281% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 34.903% |
| Yuhan Corporation | 2814.07 Billion KRW | 85.079% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 52.284% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -85.304% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 57.745% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 34.903% |
| Korea United Pharm Inc. | 468.86 Billion KRW | 10.442% |
| CKD Bio Corp. | 293.78 Billion KRW | -42.928% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 17.342% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 25.678% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -4.654% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -19.943% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 71.161% |
| Boryung Corporation | 922.36 Billion KRW | 54.475% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | 5.099% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 10.45% |
| JW Lifescience Corporation | 255.83 Billion KRW | -64.129% |